Assenagon Asset Management S.A. Vaxcyte, Inc. Transaction History
Assenagon Asset Management S.A.
- $65.1 Billion
- Q3 2025
A detailed history of Assenagon Asset Management S.A. transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Assenagon Asset Management S.A. holds 219,950 shares of PCVX stock, worth $9.84 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
219,950
Previous 47,976
358.46%
Holding current value
$9.84 Million
Previous $1.56 Million
408.15%
% of portfolio
0.01%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding PCVX
# of Institutions
324Shares Held
139MCall Options Held
229KPut Options Held
160K-
Janus Henderson Group PLC London, X014.7MShares$657 Million0.25% of portfolio
-
Vanguard Group Inc Valley Forge, PA12MShares$537 Million0.01% of portfolio
-
Ra Capital Management, L.P. Boston, MA12MShares$535 Million8.5% of portfolio
-
Black Rock Inc. New York, NY9.94MShares$445 Million0.02% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD6MShares$269 Million0.12% of portfolio
About Vaxcyte, Inc.
- Ticker PCVX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,315,100
- Market Cap $2.65B
- Description
- Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...